Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in IgA Nephropathy (QUIgAN)
NCT06350630Phase 2Recruiting
- Sponsor
- CHU Saint-Etienne
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Hydroxychloroquine with Placebo (2 arms). Primary endpoint: Absolute difference in estimate Glomerular Filtration Rate at 3 years. Started Jun 2025; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06350630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06350630.